Ftse Mib
34.374,77
0,00%
DAX
20.024,66
0,58%
S&P 500
5.868,55
-0,22%
NASDAQ
19.280,79
-0,16%
Bitcoin
96.838,75
-0,06%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NYSE Panacea Acquisition Corp (NUVB) Panacea Acquisition Corp (NUVB) Notizie

NUVB

Panacea Acquisition (NUVB)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NYSE:NUVB
DataOraFonteTitoloSimboloCompagnia
23/12/202414:00Business WireU.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung CancerNYSE:NUVBPanacea Acquisition Corp
20/12/202413:10PR Newswire (US)Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products AdministrationNYSE:NUVBPanacea Acquisition Corp
26/11/202414:00Business WireNuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx ConferenceNYSE:NUVBPanacea Acquisition Corp
13/11/202422:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:NUVBPanacea Acquisition Corp
12/11/202422:05Business WireNuvation Bio to Present at the Jefferies London Healthcare ConferenceNYSE:NUVBPanacea Acquisition Corp
06/11/202422:43Edgar (US Regulatory)Form 8-K - Current reportNYSE:NUVBPanacea Acquisition Corp
06/11/202422:41Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:NUVBPanacea Acquisition Corp
06/11/202422:05Business WireNuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business UpdateNYSE:NUVBPanacea Acquisition Corp
09/10/202422:09Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:NUVBPanacea Acquisition Corp
07/10/202422:05Business WireNuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial OfficerNYSE:NUVBPanacea Acquisition Corp
14/09/202409:05Business WirePositive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024NYSE:NUVBPanacea Acquisition Corp
09/09/202414:00Business WireNuvation Bio to Present at the Cantor Global Healthcare ConferenceNYSE:NUVBPanacea Acquisition Corp
16/08/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNYSE:NUVBPanacea Acquisition Corp
15/08/202422:46Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NYSE:NUVBPanacea Acquisition Corp
13/08/202422:02Edgar (US Regulatory)Form DEFR14A - Revised definitive proxy soliciting materialsNYSE:NUVBPanacea Acquisition Corp
05/08/202422:58Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NYSE:NUVBPanacea Acquisition Corp
05/08/202414:00Business WireNuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business UpdateNYSE:NUVBPanacea Acquisition Corp
30/07/202422:13Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNYSE:NUVBPanacea Acquisition Corp
30/07/202422:01Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNYSE:NUVBPanacea Acquisition Corp
23/07/202422:05Business WireNuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, TaletrectinibNYSE:NUVBPanacea Acquisition Corp
16/07/202415:03Edgar (US Regulatory)Form PRER14A - Preliminary Proxy Soliciting materialsNYSE:NUVBPanacea Acquisition Corp
01/06/202414:10Business WireNuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual MeetingNYSE:NUVBPanacea Acquisition Corp
29/05/202422:05Business WireNuvation Bio to Present at the Jefferies Global Healthcare ConferenceNYSE:NUVBPanacea Acquisition Corp
24/05/202422:40Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNYSE:NUVBPanacea Acquisition Corp
14/05/202422:05Business WireNuvation Bio Reports First Quarter 2024 Financial Results and Provides Business UpdateNYSE:NUVBPanacea Acquisition Corp
24/04/202416:01Business WireNuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNYSE:NUVBPanacea Acquisition Corp
10/04/202422:01Business WireNuvation Bio Completes Acquisition of AnHeart TherapeuticsNYSE:NUVBPanacea Acquisition Corp
28/03/202413:00Business WireNuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial OfficerNYSE:NUVBPanacea Acquisition Corp
25/03/202412:00Business WireNuvation Bio to Acquire AnHeart Therapeutics in All-Stock TransactionNYSE:NUVBPanacea Acquisition Corp
14/03/202421:05Business WireNuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid TumorsNYSE:NUVBPanacea Acquisition Corp
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NYSE:NUVB

La tua Cronologia

LSE
94BD
Incommun.tr.49
BITMOT
831657
Btp Tf 2,00% Fb28 Eur
TG
10A2
Amundi Msci Europe Value...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network